# Gilead Sciences

> Gilead Sciences is a VC fund backing Health Care and Biotechnology. See 67 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Foster City, United States
- Total investments: 67
- Last investment: May 2026
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/gilead-sciences
- X (Twitter): http://twitter.com/GileadSciences
- Website: http://www.gilead.com
- Facebook: https://www.facebook.com/Gilead-Sciences-162678203751209/

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases.Gilead's primary areas of focus includeHIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions.

## Contacts

5 contacts available for Gilead Sciences. Shizune tracks 14 team members at Gilead Sciences. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gilead-sciences?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 25 | 37% |
| Biotechnology | 23 | 34% |
| Non Profit | 17 | 25% |
| Therapeutics | 13 | 19% |
| Medical | 9 | 13% |

39 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 30 | 45% |
| Post-IPO Equity | 11 | 16% |
| Series B | 8 | 12% |
| Series C | 2 | 3% |
| Funding Round | 2 | 3% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 51 | 76% |
| Austria | 1 | 1% |
| United Kingdom | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Nicholas Moore | Independent Director | 2 | https://shizune.co/investors/profile/nicholas-moore |
| Stacey Ma | EVP, Head of Pharmaceutical Development & Manufacturing | 0 | https://shizune.co/investors/profile/stacey-ma |
| Ahmed Afifi | Vice President - Region Head Latin America | 0 | https://shizune.co/investors/profile/ahmed-afifi |
| Amadou Diagne | Senior Director | 0 | https://shizune.co/investors/profile/amadou-diagne |
| Brian Peters | Senior Director, Procurement | 0 | https://shizune.co/investors/profile/brian-peters-f982 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Assembly Biosciences | Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome.Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $115M | Post-IPO Equity | May 22, 2026 |  |
| Xilio Therapeutics | Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. | $40M | Post-IPO Equity | Feb 11, 2026 |  |
| Xilio Therapeutics | Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. | $35.8M | Post-IPO Equity | Dec 31, 2025 |  |
| Ensoma | Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M |  | Sep 22, 2025 |  |
| Assembly Biosciences | Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome.Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $30M | Post-IPO Equity | Dec 19, 2024 |  |
| Children's Inn At NIH | The Children’s Inn at NIH enhances the opportunities for groundbreaking medical discoveries by providing a free “place like home” that reduces the burdens of illness through a supportive environment that includes therapeutic, educational, and recreational programming for children. | $1M | Grant | Nov 22, 2024 |  |
| Assembly Biosciences | Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome.Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $12.6M | Post-IPO Equity | Jun 17, 2024 |  |
| Leap Therapeutics | Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology. | $40M | Post-IPO Equity | Apr 10, 2024 |  |
| Cypherpunk Technologies (formerly Leap Therapeutics) | Cypherpunk Technologies is a biopharmaceutical company developing antibody therapies for cancer while simultaneously executing a digital-asset treasury strategy centered on Zcash. Their oncology pipeline includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK-1, and FL-501, another antibody in preclinical development. | $40M | Post-IPO Equity | Apr 10, 2024 |  |
| SisterLove | SisterLove is on a mission to eradicate the adverse impact of HIV/AIDS and other reproductive health challenges upon women. |  | Grant | Feb 27, 2024 |  |

10 of 67 investments shown.

## Co-investors
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 6 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 6 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 5 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 5 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 4 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does Gilead Sciences invest in?

Gilead Sciences invests primarily in Health Care, Biotechnology and Non Profit startups, most often at Grant and Post-IPO Equity stage. Most of the 67 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Gilead Sciences?

Public channels for Gilead Sciences include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Gilead Sciences?

The team at Gilead Sciences includes Nicholas Moore (Independent Director), Stacey Ma (EVP, Head of Pharmaceutical Development & Manufacturing) and Ahmed Afifi (Vice President - Region Head Latin America), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co